Metastatic Hormone Refractory Prostate Cancer - Epidemiology Forecast to 2027

Metastatic Hormone Refractory Prostate Cancer - Epidemiology Forecast to 2027

  • Pages: 50
  • Geography: Global
  • Delivery Timeline:
  • Publication: Jan, 2018
  • SKU: DIEI0141
  • Single User Price
    ()
    $3,250.00
  • Site User Price
    ()
    $6,500.00
  • Enterprise Price
    ()
    $9,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's "Metastatic Hormone Refractory Prostate Cancer - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Metastatic Hormone Refractory Prostate Cancer epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027. 

Markets Covered
• United States 
• EU5 (Germany, France, Italy, Spain, and the United Kingdom) 
• Japan
Study Period: 2016-2027
Metastatic Hormone Refractory Prostate Cancer Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Metastatic Hormone Refractory Prostate Cancer in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports.
The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Metastatic Hormone Refractory Prostate Cancer outlook. It also includes the explanation of changing trends of epidemiology outlining the Metastatic Hormone Refractory Prostate Cancer scenario. 
Metastatic Hormone Refractory Prostate Cancer Epidemiology
Segmentation The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. 
The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Metastatic Hormone Refractory Prostate Cancer thereby presenting the trends with detailed analysis, with the assumptions undertaken.
The data is presented in the form of graphs along with tables to effectively summarize the landscape. 

Report Scope
• The report covers detailed overview of Metastatic Hormone Refractory Prostate Cancer explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns 
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan 
• The Metastatic Hormone Refractory Prostate Cancer Report assesses the disease risk and burden and highlights the unmet needs 
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population Key strengths 
• 10 Year Forecast 
• 7MM Coverage • Total Cases in Metastatic Hormone Refractory Prostate Cancer Key assessments 
• Patient Segmentation in Metastatic Hormone Refractory Prostate Cancer • Metastatic Hormone Refractory Prostate Cancer Risk & Burden 
• Factors driving growth in a specific Metastatic Hormone Refractory Prostate Cancer patient population

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Table 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Table 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Table 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Table 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Table 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Table 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Table 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Table 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Table 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Figure 1: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 4: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 5: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027)
Figure 6: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in United States (2016-2027) 
Figure 7: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 8: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 9: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 10: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Germany (2016-2027) 
Figure 11: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 12: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 13: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 14: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in France (2016-2027) 
Figure 15: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 16: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 17: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 18: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Italy (2016-2027) 
Figure 19: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 20: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 21: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 22: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Spain (2016-2027) 
Figure 23: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 24: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 25: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 26: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in UK (2016-2027) 
Figure 27: Prevalent/Incident Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 28: Sub-Type Specific cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 29: Sex- Specific Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027) 
Figure 30: Diagnosed Cases of the Metastatic Hormone Refractory Prostate Cancer in Japan (2016-2027)

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.